|
We asked 40 pharma leaders, what area do you think will see increased regulatory attention and enforcement in 2013?
| Foreign APIs |
30% |
GMP inspections |
18% |
| Counterfeit medicines |
30% |
| Social media and digital marketing |
9% |
| Other |
13% |
 |
|
|
|
|
|
|
|
29 January, 2013
|
| In this Issue |
New Global Alliance to Speed Up Drug Discovery
Six of the world’s leading health research centres have joined forces to form a global alliance that seeks to strengthen international academic and not-for-profit drug development. The aim of the Global Alliance of Leading Drug Discovery and Development Centres is to accelerate the translation of academic research into usable medicines and therapies ...Read more |
Banning Thimerosal in Vaccines ‘Would be a Tragedy’
Public health authorities and medical experts have challenged a provision blocking production of vaccines with the preservative thimerosal, the formulation necessary for efficient vaccine distribution in developing countries. Banning thimerosal “would be a tragedy” that puts millions of children at risk, according to the Global Alliance for Vaccines & Immunization ... Read more |
Who Lost Syria?
In the wake of the Syrian humanitarian crisis, Clark Herman looks at what Big Pharma can do to gradually restore a presence in the market ... Read more |
Read the New, Improved Pharm Exec Global Digest
In the January 2013 issue: What Now for Greece? — Brazil's War on AIDS — The African Markets Pharma Can't Ignore — and Global Safety and Harmonization Efforts 2013 ... Read more
|
Can Regulatory Professionals Make Business Leaders?
Attracting skilled regulatory staff is crucial to a company's success. But do such individuals have ahead for business? Susan Macdonald looks at how regulatory professionals can become business leaders ... Read more
|
|
|
|
